Glatiramer acetate 3X per week

Teva announced yesterday that a new version of Copaxone met its goals in a late-stage clinical trial. MSers who took the newer version of glatiramer acetate were ~34% less likely to have a relapse of their symptoms over the course of a year compared to MSers who took placebo. Copaxone is injected once a day, and the new version needs to be taken only 3x a week. Teva said the late-stage trial involved around 1,400 MSers. 


Bloomberg press release

Labels: